Background. Australia instituted funded female human papillomavirus (HPV) immunization in 2007, followed by a targeted male vaccination program in 2013. To date, Australia is one of only several countries with a funded male HPV immunization program. In 2012-2013, we conducted a survey of HPV seroprevalence in males to assess whether or not a herd impact of female vaccination could be observed.
Human papillomavirus (HPV) vaccine was registered for use in Australia in 2006, with Australia becoming one of the earliest countries to implement a female HPV vaccination program. In 2007, universal vaccination of girls aged 12-13 years began as a school-based program using 3 doses of quadrivalent HPV vaccine with an initial catch-up program for females up to 26 years of age (which concluded in 2009). The vaccine provides protection against HPV types 6, 11, 16, and 18. Australia implemented a male vaccination program in 2013 targeting boys aged 12-13 years with a 2-year catch-up campaign for boys aged 14-15 years [1] . To date, Australia remains one of only a few countries to have implemented a male program.
One reason why male programs have not been more universally implemented is because of their lower cost-effectiveness at current vaccine prices due to both a lower disease burden in males and indirect protection of males from female HPV vaccination programs [2] . Quantifying the herd protection experienced by males from female HPV vaccination programs is necessary to inform a thorough assessment of the true costs and benefits of male HPV vaccination programs. Because Australia has been at the forefront of administering HPV vaccination programs to first females and now males, Australia is well-placed to provide useful data regarding the herd protection dynamics of HPV vaccination.
To add to the existing evidence base describing HPV population seroprevalence among males, which is known to rise with age and is associated with sexual exposure to HPV as measured by lifetime number of sexual partners [3] , we conducted an HPV serosurvey among males aged 15-39 years in 2012-2013. By comparing our results against those from a baseline 2005 Australian HPV serosurvey [4] , we aimed to observe whether or not a herd protection impact of the female vaccination program against HPV targeted types could be demonstrated in males prior to the male vaccination program becoming well-established.
METHODS
We utilized the methodology established for numerous national serosurveys for vaccine-preventable diseases in Australia [5] , specifically with similar methods as those employed by Newall et al in the first (2005) HPV serosurvey internationally to obtain population based samples from women, men, and children [4] . We acquired de-identified residual diagnostic test serum samples that were collected from males aged 15-39 years between 11 January 2012 and 26 November 2013. Samples came from public and private laboratories in New South Wales (NSW), Victoria, and Queensland, which are the 3 most populous states of Australia in which 77% of the population resides [6] . Although the laboratories participating in the 2 serosurveys were not identical, both serosurveys included large laboratories from NSW, Victoria, and Queensland that received samples from across their respective states of origin. We excluded samples from individuals known to be immunosuppressed, infected with human immunodeficiency virus (HIV), or who had received multiple or recent transfusions. Our sample size estimates indicated that a collection of 800 total specimens for males across our 3 target age groups (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) , and 30-39 years) would be able to detect a difference between HPV genotype 6, 11, 16, and 18 seroprevalence levels in the present study (henceforth referred to as the second HPV serosurvey) and those of the first HPV serosurvey (conducted in 2005 prevaccination [4] ) with 95% confidence intervals of approximately +/-5% absolute prevalence difference. Serum antibody levels to HPV genotypes 6, 11, 16, and 18 were measured at PPD Vaccines and Biologics Laboratory (Wayne, Pennsylvania) using a Luminex immunoassay (cLIA) (Merck) [7, 8] . As in the first serosurvey, seropositivity was defined as having anti-HPV titers ≥20, ≥16, ≥20, and ≥24 milli-Merck units/mL for types 6, 11, 16, and 18, respectively [4] . The laboratory was blinded to the age groups of the specimens.
We calculated proportions of males seropositive per HPV type for each of the 3 target age groups. For each proportion, we calculated 95% binomial confidence intervals. Six individuals in the second serosurvey had markedly elevated titers for each of the 4 HPV types measured, consistent with those seen following vaccination [9] [10] [11] . Two each were in the age groups 15-19 years, 20-29 years, and 30-39 years. Due to the timing of the second survey (post-male vaccination implementation in Australia), which supported the likelihood that these individuals were in fact vaccinated; we censored these samples from the analysis.
We compared proportions from the second HPV serosurvey with those from the first HPV serosurvey [4] . Finally, we calculated P values to compare type-specific results between serosurveys by age group, with a P value of <.05 considered statistically significant. For analyses where numbers were too small to employ χ 2 analysis, we utilized Fisher exact test. Our analyses were performed using the Microsoft Excel, Stata version 13, and SAS version 9.3 software programs. Ethical approval was obtained from the Western Sydney Human Research Ethics Committee (HREC/12/WMEAD/65).
RESULTS
Seven hundred thirty-five samples from males aged 15-39 years were included in this serosurvey, compared with 546 in the previous serosurvey ( Table 1) .
The highest point estimates of seropositivity against single HPV types occurred among those aged 20-29 years for type 6 (7.0%), who also had the highest point estimate for HPV-18 seropositivity (1.6%). For type 11 and type 16, seropositivity was highest among those aged 30-39 years (1.4% and 6.4%, respectively). For any HPV type (positive to any of the 4 types tested for), seropositivity was highest among those aged 30-39 years (12.4%). The largest differences in seropositivity between age groups occurred for type 6, which was 5 times more prevalent among those aged 20-29 years compared with 15-19 years (7.0% compared with 1.4%) and type 16, which was approximately 9 times more prevalent in those aged 30-39 years compared with those aged 15-19 years (6.4% compared with 0.7%). Between the 2 serosurveys, there were decreases in the proportion seropositive for every HPV type and across all 3 age groups; many of these decreases were statistically significant (Table 1; Figure 1 ). The most profound decreases occurred for HPV-11, with those aged 20-29 and those aged 30-39 years experiencing an approximate 8-and 9-fold decrease in proportion positive, respectively (from 9.1% to 1.0% positive for those aged 20-29 years and from 11.2% to 1.4% positive for those aged 30-39 years). However, despite the overall reductions between the surveys in seropositivity, in the second survey ≥9% of males were seropositive for at least 1 of the 4 vaccine HPV types tested for by the age of 20 years (Table 1; Figure 1 ). The seropositivity in the samples from each male birth cohort at the 2 time points of the surveys, the ages of the men at each time point, and the HPV vaccination coverage per doses 1/2/3 in same-age females according to the National HPV Vaccination Program Register for women in NSW, Queensland (Qld) and Victoria (Vic) are shown in Supplementary Table 1 .
DISCUSSION
The results of this 2012-2013 serosurvey demonstrate a lower seroprevalence of the vaccine-specific HPV types 6, 11, 16, and 18 in males in all 3 age groups compared with results from the previous prevaccination 2005 HPV serosurvey [4] . Because the funded male immunization program was only implemented in 2013, the difference cannot be a result of male vaccination (which would increase antibody titers in the population to the targeted HPV types) and is likely due to a herd protection impact of the female immunization program, which commenced in 2007. For males [15] [16] [17] [18] [19] years of age, we had limited power to demonstrate a fall from the low pre-vaccine program levels (only 0.6%-2.4% baseline prevalence per type). The initiation of catch-up vaccination for males to age 15 years during the period of the second serosurvey, with removal of 6 males with high levels of antibodies to all 4 vaccine types suggesting vaccination from our sample, decreased our power.
Our unique findings are, to our knowledge, the first demonstration of a population-level reduction in HPV seroprevalence in males following a female vaccination program. A previous US study of HPV seroprevalence over time found no reduction in HPV seropositivity in males following female vaccination, although vaccine coverage in the United States remains lower than in Australia and males have been eligible for HPV vaccine in the United States since 2009, which may confound an ability to detect any reduction through seroprevalence estimates [12] . Our results are consistent with previous findings from Australia demonstrating herd protection from female HPV vaccination in reducing genital HPV prevalence and genital-wart incidence in males [13, 14] . Herd protection impacts from the female HPV vaccination program in unvaccinated females, as demonstrated by a fall in type-specific HPV prevalence at the cervix, have also been described previously [15] .
The methods for specimen sampling and statistical analysis we employed are well-established in Australia as a standard methodology for assessing vaccine-derived immunity in the population through serosurveillance. National serosurveillance has been undertaken to assess population-level immunity against many other diseases [5] , with results comparable to those obtained by cluster randomized sampling [16] . The main limitation of the methodology for assessment of HPV exposure as indicated through serology is that it is not possible to assess whether the sexual history of participants is representative of the population using anonymized laboratory samples. As number of sexual partners is a primary determinant of HPV seropositivity [17] [18] [19] [20] [21] , this would be important if we had reason to believe that participants were systematically different from the general population or, more importantly for our analysis, if we believed that the characteristics of the participants in relation to sexual history could have changed systematically over time. We do not believe that this is the case, with more than half of the population having at least 1 pathology test per year [22] , and also note that in Australia the median age of sexual debut is stable over time, and number of sexual partners over a lifetime is stable in males and rising in females over time [23] , meaning that confounding due to changes in sexual behavior is unlikely to be responsible for the observed decline in vaccine-targeted HPV seroprevalence in males between serosurveys.
Additional strengths of our study include the use of an identical methodology in the 2 serosurveys, including an identical antibody assay method (cLIA), limiting the potential for selection bias to explain the findings, and the blinding of laboratory staff to the age of the patients. We did not have vaccination status available for our participants, which would have been useful in interpreting the results, particularly for the participants who were seropositive to all 4 HPV types. However, because HPV vaccination produces such characteristically high antibody titers compared to natural HPV infection and across all targeted HPV types, HPV serosurveillance has in fact been used as a method for estimating HPV vaccination coverage in populations where no national vaccine register exists [9, 12] . The titers of the 6 participants in the second serosurvey who were seropositive to all types showed the markedly elevated titers characteristic of vaccination.
In addition to being used as a potential tool for estimating HPV vaccination coverage, it has been suggested that HPV serosurveillance has a role in monitoring the impact of targeted vaccine programs on the prevalence of HPV types, on the dynamics of HPV infection, and in assessing herd protection, as in our study [24] . We have previously demonstrated its utility as a baseline estimate of the relative population exposure to HPV by age and sex prior to vaccination, as has also been demonstrated in the United Kingdom, the Netherlands, and the United States, with examination of 9 HPV types recently reported prior to the implementation of nonavalent HPV vaccine [4, [25] [26] [27] [28] [29] . This is despite the limitations of HPV serology, which is a marker of cumulative HPV exposure but a marker restricted to only a small proportion of those who have a DNA-detected HPV infection demonstrated. Seroconversion is higher in females (up to 60% [24] ) than males following such HPV DNA detection, and is correlated with persistent infections and a higher viral load. Studies in males have demonstrated seroconversion rates 4-to 10-fold lower than in females [30] [31] [32] , with seroconversion related to persistence and more likely for HPV-6 than the other vaccine-targeted types [32] . Seropositivity in males has also been associated with site of infection (higher for anal infection than external genital infection) and sexual orientation (higher among men who have sex with men [MSM] than among men who have sex with women) [3, 33] . We note in particular that the extent of the decline in men aged 30-39 years in our serosurvey (Supplementary Table 1 ), although consistent with observed declines in genital warts in the same period in this age group following female HPV vaccination in Australia [34] , suggests that maintenance of seropositivity within a population cohort may require ongoing exposure. This is an important research question, with a current absence of data regarding stability of male seropositivity following natural infection over time and whether persistent infection or exposure is required to maintain detectable HPV seropositivity in males.
Our study also demonstrated that males aged ≥20 years still had substantial seropositivity for at least 1 vaccine-targeted HPV type despite the female program. This suggests that many young men still stand to benefit from male HPV vaccination. Male immunization may be particularly warranted given that MSM are at high risk for HPV infection and HPV-associated diseases but do not benefit from herd protection via female vaccination [35] . Recent studies using sensitive genotyping technologies have detected up to 95% HPV DNA prevalence in squamous cell anal cancers [36, 37] . With rates of anal cancer increasing [38] , and anal HPV infection thought to be almost universal among sexually active gay men [35, 39] , the longterm potential benefit to the health of the MSM community of a male-targeted HPV vaccination program is likely to be substantial [39] .
In summary, HPV serosurveillance can be a useful tool for depicting population trends in markers of HPV exposure, whether it be from natural infection or vaccination and, in so doing, monitor the impact of immunization programs in both vaccinated and unvaccinated cohorts. Our study has taken advantage of the high-uptake, broadly age-targeted female program in Australia and the 6-year gap until male vaccination commenced in a more limited age range. This has allowed a timely assessment of how reduced exposure in males to HPV due to vaccination of females has impacted population-level seroprevalence. These surveillance data will be of interest beyond Australia, as models supporting future HPV vaccination programs are further refined to more accurately represent the impact of vaccination on herd protection. Better control of HPV, and of HPV-related diseases in both female and males, can be achieved by gender-neutral vaccination programs [40, 41] . Models, calibrated against studies such as ours, can help to determine at what vaccine cost such vaccination programs could be cost-effective.
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